Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Treasury Shares: 2020-2024

Historic Treasury Shares for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $6.1 million.

  • Arcutis Biotherapeutics' Treasury Shares fell 4.59% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year decrease of 4.59%. This contributed to the annual value of $6.1 million for FY2024, which is 106.69% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Treasury Shares stood at $6.1 million for FY2024, which was up 106.69% from $2.9 million recorded in FY2023.
  • In the past 5 years, Arcutis Biotherapeutics' Treasury Shares registered a high of $6.1 million during FY2024, and its lowest value of $162,930 during FY2020.
  • Its 3-year average for Treasury Shares is $3.5 million, with a median of $2.9 million in 2023.
  • Data for Arcutis Biotherapeutics' Treasury Shares shows a peak YoY soared of 370.33% (in 2022) over the last 5 years.
  • Over the past 5 years, Arcutis Biotherapeutics' Treasury Shares (Yearly) stood at $162,930 in 2020, then skyrocketed by 105.73% to $335,196 in 2021, then surged by 370.33% to $1.6 million in 2022, then skyrocketed by 85.83% to $2.9 million in 2023, then spiked by 106.69% to $6.1 million in 2024.